Our goal is to obtain the most accurate information that we know will fundamentally affect individuals' lives and to provide clinicians with the most reliable advice for their decisions.

Please enter subscribe form shortcode

28 June 2023

ESHRE 39th Annual Meeting

ESHRE 39th Annual Meeting

ESHRE 39th Annual Meeting

154 154 people viewed this event.

We are reporting from #ESHRE2023📢
Since its first use in 1990, preimplantation genetic diagnosis (PGD) has played an important role among assisted reproductive techniques, making it possible to investigate genetic abnormalities during the IVF process and select healthy embryos for transfer.

The impact of trophectoderm biopsy for PGD on maternal and newborn health was discussed by Prof. Dr. Cynthia Sites from the University of Massachusetts, while Prof. Dr. Willem Verpoest from UZ Brussel shared his experience on freeze-thaw procedures for embryo repeat testing.

Sites compared 585 post-biopsy transfers with 2191 non-biopsy pregnancies to investigate the effects on pregnancy and birth of trophectoderm biopsies taken for genetic examination of embryos after freezing during IVF. As a result of the study, no difference was observed between the groups in the health parameters of preeclampsia, hypertension, placental abnormalities, preterm birth, low-weight birth, cesarean section and gestational diabetes mellitus that started with pregnancy. Sites stated that trophectoderm biopsy from the embryo for PGD is a safe method for maternal and newborn health.

Verpoest has stated in various publications that PGD procedures may be repeated in 2-12% of cases for biological or technical reasons, and that during this process it is necessary to take a biopsy of the frozen embryos for 2. He stated that if the freeze-thaw procedure is performed in professional laboratories, it is applicable in terms of its diagnostic importance and the completion of the reproductive process.


Event registration closed.

Date And Time

2023-06-25 to

Registration End Date


Share With Friends